Neurophysiologic evaluation of cyclosporine toxicity associated with bone marrow transplantation
- 29 January 2009
- journal article
- case report
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 92 (5) , 423-429
- https://doi.org/10.1111/j.1600-0404.1995.tb00158.x
Abstract
Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Our institutions averages 35 allogeneic BMT's per year. In the past year we have seen two women with reversible cortical blindness secondary to CSA toxicity. Age (years) (Case 1; Case 2): 32; 22. Day post-BMT: 41: 50. Peak CSA level (ng/ml): 1159; 632. Both had a history of renal toxicity requiring adjustment of CSA dosage. MRI - both with diffuse white matter changes. EEG-both with moderate to severe generalized slowing. Visual evoked potentials were markedly prolonged in both. Auditory evoked potentials: minimally abnormal; normal. Somatosensory evoked potential - both normal. Prompt improvement occurred with discontinuation of CSA. Followup neurophysiologic evaluations were normal, however structural changes remain on MRI. As neurophysiologic studies closely follow the clinical status they should be included in the evaluation and followup of CSA neurotoxicity.Keywords
This publication has 18 references indexed in Scilit:
- Cyclosporine NeurotoxicityNew England Journal of Medicine, 1991
- Progressive multifocal leukoencephalopathy after cardiac transplantationNeurology, 1988
- Cyclosporine-Associated Central Nervous System ToxicityNew England Journal of Medicine, 1988
- Central Nervous System Toxicity after Liver TransplantationNew England Journal of Medicine, 1987
- Cerebral blindness and encephalopathy with cyclosporin A toxicityNeurology, 1987
- CYCLOSPORINE-ASSOCIATED CENTRAL NERVOUS SYSTEM TOXICITY AFTER ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1984
- Complex Visual Hallucinations and CyclosporineArchives of Neurology, 1984
- Nephrotoxicity of Cyclosporin a after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1981
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979